SCHEMBL6721785

SCHEMBL6721785

Cc1cc(N)ccc1C(=O)C1=C(O)C(=O)N(c2ncc(S(=O)(=O)c3ccccc3)s2)C1c1cccc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.51
ALDH1A1 P00352 4/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 6/20 0.42
RXFP1 Q9HBX9 4/20 0.42
PPARG P37231 2/20 0.42
NCOR2 Q9Y618 1/20 0.42
MAP3K5 Q99683 5/20 0.42
CCR1 P32246 1/20 0.40
MEN1 O00255 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MAPT P10636 3/20 0.40
USP2 O75604 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 2/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721838 0.92 PTGES (0.52) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6721890 0.92 PTGES (0.52) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6721966 0.91 PTGES (0.48) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6722044 0.90 PTGES (0.49) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6721747 0.90 PTGES (0.56) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6722113 0.88 PTGES (0.47) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6721714 0.87 PTGES (0.56) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6722108 0.86 PTGES (0.49) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6722006 0.86 PTGES (0.49) PTGESALDH1A1PKMKMT2ARXFP1
SCHEMBL6721764 0.85 PTGES (0.58) PTGESALDH1A1PKMKMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS TYMP, IMPDH1, SAMHD1 PTGES 3330/4885ALDH1A1 265/4885PKM 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.